Guy Wingate, PhD

GlaxoSmithLline PLC (Retired)
Independent Consultant
Dr. Wingate is recently retired from GSK where he was Head of the Global Transformation Office for Environmental Sustainability. He was previously VP & Compliance Officer for Global Manufacturing & Supply Chain, responsible for assuring there was a robust internal control framework and effective risk management in place across the integrated manufacturing and supply chains. He has also had periods of additional responsibility for GSK Third-Party Oversight, acting as Global Risk Officer supporting the GSK Corporate Executive Team, and being GSK’s Single Point of Contact (SPOC) for European Medicines Agency on COVID-19 supply continuity matters during the 2020/21 pandemic. Dr. Wingate has been associated with GAMP since its origin with roles of increasing responsibility, chaired GAMP Council between 2000 and 2010, led the development of GAMP4 and GAMP5, and was member of the ISPE International Board of Directors between 2008-2012.

Related Articles

Sustainability: Corporate Ambition, Governance, & Accelerated Delivery
Features
Sustainability: Corporate Ambition, Governance, & Accelerated Delivery

The imperative for global action to tackle climate change is clear and the pharmaceutical industry has a key role to play. Governments have entered into international commitments to reduce climate impact (carbon emissions) and protect nature (water, land, air, and biodiversity) with policy frameworks established to facilitate and drive progress against agreed targets.1